In vitro antiproliferative effects of nab-paclitaxel with liposomal cisplatin on MDA-MB-231 and MCF-7 breast cancer cell lines.
In this study, the in vitro cytotoxic effect of nanotechnological drugs nab-paclitaxel and liposomal cisplatin combination was evaluated on MDA-MB-231 and MCF-7 breast cancer cell lines. For this purpose cell viability, cell index values obtained from xCELLigence RTCA (Real-Time Cell Analysis) DP instrument, mitotic index (MI), apoptotic index (AI) and labelling index (LI) analysis among cell kinetic parameters were used. A1L25: 1 μg/ml nab-paclitaxel+25 μg/ml liposomal cisplatin, A1L5: 1 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin and A10L5: 10 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin for MDA-MB-231 cell line and A1L5: 1 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin, A1L10: 1 μg/ml nab-paclitaxel+10 μg/ml liposomal cisplatin and A5L1: 5 μg/ml nab-paclitaxel+1 μg/ml liposomal cisplatin doses for MCF-7 were applied for 24-72 hrs. Significant decrease in cell viability and cell index values for both cell lines was observed, while the MI and LI values of both cell lines increased at 24 hrs, and decreased significantly at 72 hrs. Also there was a significant increase in the AI values. Nab-paclitaxel and liposomal cisplatin offer a promising treatment modality in different breast cancer subtypes.